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Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary arterial hyper-
tension characterised by a progressive obstruction of small pulmonary veins that leads to
elevation in pulmonary vascular resistance and right ventricular failure. Despite improved
understanding and more efficacious treatment options for PAH overall, the prognosis of PVOD
remains dismal. Without therapeutic intervention few patients would be expected to survive
more than two years. PVOD may occur in both idiopathic and heritable forms, or develop in
association with connective tissue disease, chronic respiratory disease, malignancy or bone
marrow transplantation, among other causes. A widespread fibrous intimal proliferation that
predominantly involves the pulmonary venules and small veins is the key histopathological
hallmark. Surgical lung biopsy is considered the definitive diagnostic test but is associated with
significant risk and is not recommended. Distinguishing PVOD from PAH on clinical grounds
alone is generally not possible, although PVOD is characterised by a higher male/female ratio
and higher tobacco exposure. Instead, non-invasive tests may be helpful and the diagnosis is
usually based on an integrated assessment that incorporates high resolution computed tomog-
raphy (septal lines, ground-glass opacities and lymph node enlargement), pulmonary function
testing (lower DLCO), arterial blood gas analysis (lower PaO2 at rest) and bronchoalveolar
lavage (occult alveolar haemorrhage). Treatment of PVOD remains challenging as exposure
to pulmonary vasodilators and PAH-specific agents may precipitate acute pulmonary oedema.
Nonetheless, a number of successful outcomes describing cautious use of prostanoids, en-
dothelin antagonists and phosphodiesterase type-5 inhibitors have been described.45 37 47 72; fax: þ33 1 46 30 38 24.
c.aphp.fr (M. Humbert).
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remains the treatment of choice.
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Over the last quarter of a century, there have been signifi-
cant advances in the field of pulmonary arterial hypertension
(PAH). Improved understanding of the genetic, molecular
and cellular mechanisms that characterise the disorder has
led to the development of a number of targeted therapies
that act on distinct pathways and confer significant
improvements in symptoms, exercise capacity and possibly
prognosis. Pulmonary veno-occlusive disease (PVOD) is a rare
form of PAH that remains poorly understand and is both
difficult to diagnose and effectively treat. Pathologically,
PVOD is characterised by an obliterative fibrotic vasculop-
athy, predominantly affecting the smaller branches of the
pulmonary venous tree.1 Prognosis relates to the degree of
associated right ventricular dysfunction that results from
progressive elevation of pulmonary vascular resistance.
Following the Second World Symposium on Primary
Pulmonary Hypertension (Evian, France 1998), a new
treatment-based classification was adopted. This classifi-
cation recently updated in 20082 proposed grouping
together different forms of pulmonary hypertension for the
first time, based not only on shared underlying pathophys-
iological mechanisms, but also on predicted therapeutic
responses. This framework has served to not only allow the
evaluation of relatively large numbers of patients in rand-
omised studies of investigational drugs, but also facilitate
the development of novel agents that specifically target
aberrant molecular mechanisms characteristic of different
forms of the disease. The recognition that PVOD patients
represent a subgroup of PAH with distinct clinical features
and outcomes is reflected in the most recent update of the
classification system of pulmonary hypertension.2 It was
decided that PVOD be placed, together with pulmonary
capillary haemangiomatosis (PCH), in a separate but
related group to PAH, referred to as Group 1’. A diagnosis
of PVOD should be entertained in cases of precapillary
pulmonary hypertension with associated radiological
evidence of pulmonary oedema but normal left heart
function. Histological proof is required for a definitive
diagnosis of PVOD; however, this approach is potentially
hazardous in patients with pulmonary hypertension and
surgical lung biopsy is not recommended. Moreover, a non-
invasive investigative approach can be employed to facili-
tate a confident diagnosis in the majority of cases.3 Another
important clinical hallmark of PVOD is that patients
exposed to novel PAH-specific treatments may experience
an abrupt and potentially life-threatening deterioration.4
Clinical worsening as a result of disease progression is
almost universal and few patients are alive more than two
years after diagnosis.5 Thus, PVOD remains a challenging
entity even for experienced clinicians, from both a diag-
nostic and therapeutic standpoint. This review summarises
current insights into the understanding of the pathophysi-
ology of PVOD and highlights recent therapeutic advances.Epidemiology and risk factors
Although first described by Hora in 1934,6 it was not until
the 1960s that PVOD was generally accepted as a separate
clinical entity.7 The true incidence and prevalence rates
are difficult to define, since many cases are likely mis-
diagnosed as precapillary PAH. Data from ourselves and
others estimate that PVOD may account for approximately
10% of PAH cases overall.3,8e10 Based on data from the
French National PAH Registry, we estimate that the annual
incidence of PVOD is approximately 0.1e0.2 cases per
million in the general population.1,11 However, this may
represent an underestimation of the true incidence of the
disorder. Whereas idiopathic PAH shows a distinct female
preponderance, PVOD is characterised by a higher male/
female ratio.3 In addition, PVOD also appears to be more
common in young adults and children, although a broad age
range exists and cases have been reported in both extremes
of age.3
Pathogenesis
In most cases, the aetiology of PVOD is unknown. Given the
rarity of the disorder, defining potential causes is difficult.
Numerous associations have been reported and it is probable
that disease pathogenesis is multifactorial. Whether PVOD
occurs in an idiopathic form or as a complication of other
diseases, an exaggerated response to an initial endothelial
injury has been proposed as an inciting event, leading to
activation of aberrant repair mechanisms and ultimately
a widespread fibrosis of the pulmonary vascular tree.12
Genetic factors
Clinical and experiment evidence suggests that PVOD may
have a possible genetic basis. A number of published reports
have described fatal occurrences that appeared to have
a familial pattern, although a non-heritable risk factor could
not definitively be excluded in these cases.13,14 Data indicate
that germlinemutationswithin the coding region of the type-
II bone morphogenic protein receptor gene (BMPR2),
a member of the transforming growth factor-ß receptor
superfamily, are present in 50% of familial cases and at least
25% of sporadic cases of idiopathic PAH.15 In the lung, the
BMPR-II receptor is predominantly expressed on and modu-
lates function of vascular endothelium and smooth muscle
cells.16 In those carrying the mutation, BMP-mediated
protection from dysregulated vascular proliferation and
remodelling is reduced or lost. Recent work has highlighted
that PAH patients carrying the mutation develop the disease
at a younger age and are characterised by a more aggressive
phenotype compared with idiopathic PAH patients.17 Inter-
estingly, mutations in several loci of the BMPR2 gene have
nowalso been reported inPVODpatients, suggesting a similar
Pulmonary veno-occlusive disease S25pattern.3,18e20 In highlighting the genetic similarities that
exist between the different forms of obstructive vasculop-
athy that affects the lung, these observations have fuelled
speculation that PVOD may in fact represent a variant of
idiopathic PAH that predominantly affects the venous aspect
of the pulmonary circulation.21
Toxic exposures
Several anecdotal reports have proposed that exposure to
different cytotoxic agents may be aetiologically relevant.
Cases of PVOD diagnosed in the context of treatment with
a number of chemotherapeutic regimens have formed the
basis of this association. Mitomycin, bleomycin, cisplatin,
vincristine, cyclophosphamide and carmustin have variously
been implicated in disease pathogenesis.22,23 PVOD has also
been reportedas a complicationof leukaemia, lymphomaand
several different solid forms of organ malignancy.24e27
Peripheral blood stem cell transplantation,12 autologous
and allogenic bone marrow transplantation28,29 solid organ
transplantation30 and radiotherapy25 have additionally been
described as potential risk factors. However, the relative
infrequency of these different associations highlights the
difficulty in establishing whether it is the disease or its asso-
ciated treatment that is responsible for the onset of PVOD.
Results from different patient series indicates that there
is an increased incidence of PVOD in cigarette smokers
compared to their non-smoking counterparts.1,3,31 Inter-
estingly, previous investigators have shown that animals
exposed to tobacco smoke exhibit histological evidence of
small pulmonary artery muscularization with associated
elevated pulmonary artery pressures. These injurious
effects are likely the result of upregulated gene expression
of various vasoactive mediators.32 Whether similar mecha-
nisms might be of pathological relevance in PVOD requires
additional study.
Inflammatory disorders
Support for the hypothesis that the development PVOD may
have, at least in part, an immunologic basis is derived from
data from isolated reports of the disorder arising in asso-
ciation with a number of autoimmune disorders. Cases of
PVOD complicating sarcoidosis,33 Langerhans’ cell gran-
ulomatosis,34 chronic active hepatitis,35 Hashimoto’s
thyroiditis,36 systemic lupus erythematosis,37 rheumatoid
arthritis,37 systemic sclerosis,38e40 mixed connective tissue
disease41 and celiac disease35 have been reported. A
number of potential mechanisms to explain the develop-
ment of PVOD in patients with these various inflammatory
disorders have been postulated, though these hypotheses
remain speculative owing to a lack of corroborative
evidence. Moreover, the heterogeneous nature of the
different diseases that have been linked with PVOD
suggests that involvement of several contributory patho-
physiological factors may be necessary.
Histopathological characteristics
PVOD is a fibrotic disease process that predominantly
involves the venules and small veins in the interlobularseptae of the pulmonary tree with relative sparing the
larger veins of the hilum.42 The walls of affected small
pulmonary veins are generally thickened as a result of
disorganized smooth muscle hypertrophy and collagen
matrix deposition. As a result, the lumina of these vessels is
significantly narrowed or occluded, frequently resulting in
overt intraluminal thrombosis. Evidence of recanalization
with single or multiple lumina may also be apparent in
occluded vessels.
Long-standing venous injury is frequently accompaniedby
proliferation of smooth muscle and calcium-encrusted
elastic fibres, resulting in “arterialization” of pulmonary
veins that, when sufficiently extensive, may be confused
with pulmonary arteries. The lung may be involved in a pat-
chy or diffuse pattern, with an underlying fibrotic intimal
proliferation that often shows a spectrum from a loose,
oedematous and hypocellular fibro-myxoid appearance to
one that is dense, collagen-rich and sclerotic, depending on
the region examined and stage of disease.43 Resident alve-
olar macrophages and type-II pneumocytes frequently
contain abundant haemosiderin as a result of chronic passive
congestion and occult haemorrhage.44 This pattern is
frequently accompanied by extensive haemosiderin deposi-
tion in the interstitium that may lead to an erroneous diag-
nosis of pulmonary vasculitis or idiopathic pulmonary
haemosiderosis.
Although the predominant lesions in PVOD are found in
the pulmonary veins and venules, both the arterial and
capillary components of pulmonary vasculature are often
concomitantly involved. Rounded muscularized pulmonary
arteries in patients with PVOD generally show medial
hypertrophy and eccentric intimal fibrosis. These key
histological characteristics are shared with PAH. However,
plexiform lesions, often abundant in lungs of PAH patients,
are not found.45,46 Colander-like lesions resulting from
organization of arterial thrombus are characteristic.
Pulmonary arterioles, which generally lack vascular smooth
muscle, may additionally become muscularized as a result
of chronically increased upstream afterload. Alveolar
capillaries characteristically show dilatation and conges-
tion that may be sufficiently prominent to produce an
angioma-like capillary appearance on occasion.43
An important differential diagnosis of PVOD is PCH which
is distinguished by abundant but well-circumscribed capil-
lary proliferation. The eventual consequence of PCH is an
obstructive pulmonary arteriopathy that may be difficult to
distinguish from PVOD, as shown in a recent study by Lan-
tuejoul et al.42 These investigators re-examined 35 cases
originally labelled as either PVOD or PCH on the basis of
histopathological assessment and found evidence of pulmo-
nary arterial lesions considered more typical of PAH in the
majority of PVOD cases. Furthermore, four out of five
patients originally classified as PCH showed additional
evidence of significant venous and arterial obstructive vas-
culopathy. These observations have led to speculation that
PVOD and PCHmay in fact represent two variants of the same
disease.
de Montpreville et al. recently reported their findings in
a series of 19 PVOD patients, focusing on lymphoid tissue
abnormalities in explanted lungs.45 Dilatation and congestion
of lymphatic vessels characterised by ectasic sinuses were
prominent or moderate in appearance in 15 cases.45 Vascular
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channels was also typical. Lymphoid follicular hyperplasia
within subsegmental and segmental lymphnodeswasanother
consistently observed feature.45 Interestingly, lesions were
evident in both pathologically enlarged and smaller lymph
node groups. In contrast, these various findings were rarely
observed in pulmonary hypertension of other causes.
Diagnostic approach
Definitive diagnosis of PVOD requires histological examina-
tion of surgical lung biopsy specimens. However, this proce-
dure is associated with a significant mortality risk in patients
with established pulmonary vasculopathy and is generally
avoided.47 Pathological confirmation is thus rare prior to
autopsy or explant and treatment decisions are usually based
on clinicoradiologic grounds. The current authors have
demonstrated that a non-invasive diagnostic approach using
high resolution computed tomography (HRCT) of the chest,
arterial blood gases, pulmonary function tests, and bron-
choalveolar lavage could be helpful in detecting patients
with PVOD, thereby avoiding recourse to high-risk surgical
lung biopsy for histological confirmation.
Clinical presentation
As is the case with other forms of pulmonary hypertension,
the non-specific nature of clinical presentation of PVOD
likely contributes to the delay between onset of symptoms
and definitive diagnosis. As observed in other forms of PAH,
affected individuals most frequently report dyspnoea,
exercise limitation, fatigue and syncope. Haemoptysis may
also occur but is rarely massive. Progressive worsening of
symptoms is typical, though PVOD manifesting acutely or
even presenting with sudden death has been described.42
Physical examination is characterised by typical signs of
pulmonary hypertension. Affected individuals may demon-
strate a left-sided parasternal lift indicative of right
ventricular hypertrophy. Typical features detectable by
cardiac auscultation include an accentuated pulmonic
component to the second heart sound, a pansystolic
murmur of tricuspid valve regurgitation or diastolic murmur
of pulmonary valve regurgitation and a right ventricular
additional third or fourth sound. Additional evidence of
right ventricular insufficiency (cyanosis, elevation of the
jugular venous pulse, hepatomegaly, ascites and oedema of
the lower limbs) should be sought. Distinguishing PVOD
from PAH on clinical grounds alone is difficult since physical
findings are often identical. Digital clubbing and Raynaud’s
phenomenon have been associated with PVOD but are
observed no more frequently than in idiopathic PAH.1
Auscultatory crackles are usually indicative of acute
pulmonary oedema, particularly in the context of PAH-
specific therapy.
Transthoracic echocardiography
Transthoracic echocardiography is an important initial non-
invasive diagnostic tool in the evaluation of all patients in
whom pulmonary hypertension is suspected.48 A systolic
pulmonary artery pressure (PAP) cut-off of greater than40 mmHg, as estimated by the velocity of the regurgitant
jet of flow through the tricuspid valve is a sensitive but not
a specific diagnostic threshold. False positives using this
value are common and formal diagnosis of pulmonary
hypertension requires confirmation by right heart cathe-
terization.49 Furthermore, there are no distinct echocar-
diographic features that help distinguish PVOD from other
forms of pulmonary hypertension. Nonetheless, echocardi-
ography is useful to exclude the presence of associated left
ventricular, valvular or pericardial abnormalities.Right heart catheterization
All patients suspected of having PVOD on the basis of clin-
ical assessment and non-invasive testing should undergo
right heart catheterization in order to confirm the diagnosis
and establish the extent of haemodynamic perturbation.
The presence of pulmonary hypertension is confirmed by
a mean PAP >25 mmHg at rest. In PVOD, measured values
of the pulmonary capillary wedge pressure (PCWP) are
characteristically in the normal range (i.e. less than
15 mmHg) despite the increase in afterload that is the
result of vasculopathy within directly upstream pulmonary
venules and smaller branches of the pulmonary veins. This
is because the term PCWP is somewhat misleading since
pressure measurements that are recorded when a catheter
is wedged in a branch of the pulmonary artery reflect
pressures in the larger veins which are typically unaffected
by the disease process. In PVOD therefore, the apparently
normal values of PCWP do not represent a true reflection of
the true capillary pressure. Furthermore, in most cases it is
apparent that PVOD variably affects the smaller venous
structures of the lung, while a portion of collateral bron-
chial venous tributaries and unaffected portions of the
pulmonary venous tree generate an apparently normal
venous return to the larger veins and left heart. As a result,
PVOD is characterised by a pattern of precapillary PAH on
right heart catheterization even though the anatomic
obstruction is predominantly postcapillary.3
A vasodilator trial using short acting agents such as
inhaled nitric oxide (NO), epoprostenol or adenosine at the
time of catheterization is recommended for patients with
PAH in order to identify those likely to have a favourable
long term response to calcium channel antagonist therapy.50
However, administration of NO or other short acting
pulmonary vasodilators to assess for acute vasoreactivity
has been linked to the development of acute pulmonary
oedema and must be performed with caution in those with
suspected PVOD.51
Interestingly, we reported that short duration (less than
10 min) exposure to 10 ppm inhaled NO was not associated
with any instances of acute pulmonary oedema among
a cohort of 24 histologically confirmed PVOD patients,
suggesting this diagnostic tool may be safely performed.1
However, results from acute vasodilator testing in this
series did not predict which individuals subsequently devel-
oped PAH-specific therapy associated pulmonary oedema.
Furthermore, patients with evidence of acute vasoreactivity
with NO administration, generally a favourable prognostic
sign in idiopathic PAH, may develop life-threatening pulmo-
nary oedema after initiation of calcium channel
Figure 1 Computed tomography of the chest in patients with PVOD shows a broad range of manifestations. Typically, diffuse
poorly-defined centrilobular nodular opacities with associated septal line thickening (Panel A), associated mediastinal lymph node
enlargement (arrow, Panel B) and enlargement of right heart chambers are observed (star, Panel C). However, less characteristic
patterns such as widespread confluent ground-glass opacification (Panel D) may also be seen, leading to considerable diagnostic
difficulty.
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be little merit of systemically performing vasodilator studies
in those with a strong clinical suspicion of PVOD, since the
haemodynamicfindings areunlikely to impact on therapeutic
decisions.1,3
Imaging studies
Radiologically PVOD may be suspected when the combina-
tion of pulmonary artery enlargement, features of post-
capillary congestion and a normal-sized left atrium and
major pulmonary veins are seen.52 Septal Kerley B lines in
a subpleural distribution, interstitial oedema and pleural
effusions are the principal plain chest radiograph clues to
a postcapillary location of vascular obstruction. A more
diffuse alveolar pulmonary oedema pattern is an additional
important finding, particularly in the context of exposure to
PAH targeted treatment, though similar patterns may be
seen in PVOD complicated by pulmonary haemorrhage,
infarction or infection.
HRCT is an important diagnostic modality in the evalua-
tion of suspected PVOD.1,53 Radiological evidence of the
haemodynamic consequences of pulmonary hypertension
are invariably present, characterised by central pulmonary
arterial enlargement, right ventricular hypertrophy and
dilatation and bowing of the interventricular septum. By
contrast, the left-sided cardiac chambers are of normal size.
The triad of diffuse ground-glass opacification, particularly
in a centrilobular distribution, septal thickening and medi-
astinal lymph node enlargement is common and highlysuggestive of PVOD in patientswith features of PAH (Fig. 1).53
Pleural and pericardial effusions are frequently observed
and often portend a poor prognosis, though occur no
more commonly than in idiopathic PAH.53,54 Widespread
pulmonary nodules, with or without associated more exten-
sive alveolar consolidation has also been described.
Ventilation perfusion lung scintigraphy is of limited
diagnostic utility in PVOD since scans are commonly normal
or may show a range of non-specific or even misleading
patterns.52,55 Indeed, evidence of multiple mismatched
segmental and subsegmental perfusion defects have been
reported, leading to diagnostic confusion with idiopathic or
chronic thromboembolic pulmonary hypertension.56
Bronchoscopy
Recently published data suggests that bronchoalveolar
lavage (BAL) may be helpful in the workup of suspected
PVOD. Using BAL samples from 19 patients without overt
evidence of haemoptysis, Rabiller et al showed that
PVOD patients have significantly increased numbers of
haemosiderin-laden macrophages and higher average Golde
scores compared to idiopathic PAH.31 This observation
suggests that occult alveolar haemorrhage is relatively
common in PVOD and its detection in cases of presumed
idiopathic PAH should prompt clinicians to entertain an
alternate diagnosis (Fig. 2). However, transbronchial biopsy
should not be performed, since it is of no additional diag-
nostic value and is associated with an unacceptably high
complication ratewhen performed in this patient population.
Figure 2 Management of pulmonary veno-occlusive disease (PVOD) at the French Referral Center for Pulmonary Hypertension. In
patients with precapillary pulmonary hypertension, the diagnosis of highly probable PVOD is based on a non-invasive diagnostic
approach, including arterial blood gas, diffusing capacity of the lung for carbon monoxide (DLCO), arterial oxygen saturation
measured by pulse oximetry (Sp,O2) during 6-min walk test (6MWT), high-resolution chest tomography (HRCT) of the chest and
bronchoalveolar lavage (BAL). Lung biopsy is not recommended in these patients. Patients with suspected PVOD receive
conventional therapy (warfarin, diuretics and oxygen if needed) for pulmonary arterial hypertension (PAH). Cautious use of specific
PAH therapies is required in these patients because of the risk of severe pulmonary oedema. Oral therapy may be considered for
PVOD patients in New York Heart Association (NYHA) functional class II and III. In patients in NYHA functional class IV, continuous
intravenous epoprostenol when used with caution may improve functional and haemodynamic parameters and may be considered
as a bridge-therapy for lung transplantation. mPAP: mean pulmonary artery pressure; PcwP: pulmonary capillary wedge pressure;
PaO2: arterial oxygen tension; DLCO: diffusing capacity of the lung for carbon monoxide; IPDE5: phosphodiesterase type-5 inhib-
itor; ERA: endothelin receptor antagonists.
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A spectrum of abnormalities of pulmonary function has
been described in PVOD patients (Fig. 2). Spirometric
values are most often normal or show a mild restrictive
pattern, though an obstructive ventilatory defect has been
described.51 Lung volumes are usually in the normal range.1
Measures of forced expiratory volume in one second (FEV1),ratio of FEV1/forced vital capacity and total lung capacity
are of low discriminatory value in distinguishing PVOD from
idiopathic PAH.1 However, measurements of the single-
breath diffusing capacity for carbon monoxide (DLCO) are
often significantly reduced, and to a greater degree than is
the case in idiopathic PAH patients. We have previously
shown that a DLCO of <55% predicted may be useful to
screen for PVOD cases among patients with suspected
Pulmonary veno-occlusive disease S29idiopathic PAH.1 However, it is important to note that
values for DLCO may be overestimated in the context of
PVOD, at least temporarily, because of the frequent asso-
ciation with occult alveolar haemorrhage and values in the
normal range do not exclude the diagnosis.
Data from several studies have shown that PVOD
patients are characterised by significantly lower resting
partial pressure of arterial oxygen compared to those with
idiopathic PAH, a finding may be helpful in distinguishing
the two disorders.3,51 In addition, a lower nadir arterial
oxygen saturation measured by pulse oximetry during 6 min
walk test may also be diagnostically useful.1 Several factors
common to the disorder may account for this pattern, with
pulmonary oedema, alveolar haemorrhage, diffusion
impairment and ventilationeperfusion mismatching all
considered mechanistically important.3
Therapy
Pulmonary vasodilators
In recent years, remarkable advances in the pharmacologic
options available to clinicians treating PAH patients have
been made. Regulatory approval has now been granted for
a number of drug therapies thatmanifest pulmonary-specific
vasodilatory and antiproliferative effects, resulting in
meaningful and sustained improvements in relevant clinical
parameters. Indeed, refinements in the understanding of
the molecular characteristics of PAH and subsequent
discovery of agents that modify these aberrant pathways is
one of the most important breakthroughs in the entire field
of pulmonary vascular diseases of the last 25 years.
Since the Third International Symposium on PAH, held in
2003, PVOD has been included in Group 1 (pulmonary
arterial hypertension). However, prospective studies eval-
uating novel targeted PAH therapies have generally
excluded PVOD patients. This is principally due to a number
of published observations of severe and occasionally fatal
adverse outcomes with these treatments.1,4 Since the
obstructive vasculopathy that is the hallmark of PVOD is
predominantly located on the venous aspect of the
pulmonary circulation, treatment with PAH-specific vaso-
dilator therapies may cause an augmentation of pulmonary
arteriolar blood flow against the fixed resistance of
occluded pulmonary venules and veins. The resultant
increase in the transcapillary hydrostatic pressure gradient,
manifest initially as subpleural interlobular septal line
thickening, may progress to severe pulmonary oedema.
Indeed, when initiation of medical therapy for presumed
idiopathic or connective tissue disease associated-PAH fails
to produce clinical improvement or is associated with the
development of life-threatening pulmonary oedema,
a diagnosis of PVOD should be entertained. It is likely that
this phenomenon is due to a selective effect of these agents
on the pulmonary arterial tree without associated pulmo-
nary venodilation that produces in an abrupt increase in
transcapillary hydrostatic pressure, resulting in transuda-
tion of fluid into the pulmonary interstitium and alveoli.
Screening for PVOD should be performed for all PAH
patients to exclude this diagnosis prior to commencing
vasodilator therapy.54In addition to safety concerns, the rarity of PVOD as
a clinical entity further limits the numbers of patient that
might be recruited to randomised controlled trials of
existing or novel therapies. As a result, most of the pub-
lished data describing treatment-related outcomes are
derived from anecdotal case reports and small series and to
date no controlled studies of drug treatments for PVOD
have been performed. In fact, lung or combined heartelung
transplantation have long been considered the only effec-
tive intervention for patients, with PAH-specific agents
regarded as adjuncts primarily reserved as bridges to
transplantation.General measures
A number of additional measures are routinely advised for
PVOD patients, although these are mostly based on expert
consensus, often with extrapolation from historical studies
in other diseases. Empiric evidence from well-designed
prospective clinical trials to support the use of most of
these “conventional” therapies is lacking as published
studies are mostly of a retrospective or uncontrolled nature.
Indeed, some of these interventions likely offer only symp-
tomatic benefits without necessarily impacting on prognosis.
Nevertheless, their application is biologically plausible and
thus broadly advocated.57 General recommendations
include limiting of physical activity to tolerance and avoid-
ance of concomitant medications that can potentially
aggravate pulmonary hypertension (such as b-adrenergic
receptor blockers) or interfere with the metabolism of
vitamin K antagonist anticoagulation therapy.
Supplemental oxygen should be considered for individ-
uals with resting or exercise-induced hypoxaemia in order
to maintain arterial oxygen saturation greater than 90%.
Vaccinations to prevent pneumococcal pneumonia and
influenza are advised. Given a possible aetiological link
between tobacco exposure and PVOD, smoking cessation
advice and appropriate pharmacotherapy are particularly
important and should routinely be offered to cigarette
smokers. Warfarin anticoagulation, which is routinely used
in idiopathic PAH, should be prescribed with caution in
PVOD given the association with occult alveolar haemor-
rhage.31 Diuretics offer symptomatic benefit in those with
right ventricular volume overload that is not controlled by
dietary measures alone. The effect of diuretics on mortality
in PVOD has not been systemically examined.
The additional haemodynamic stresses of pregnancy and
delivery are poorly tolerated in PVOD patients, being
associated with increased rate of deterioration and very
high mortality rates. Moreover, commonly prescribed
treatments (e.g. warfarin and bosentan) are known
teratogens. Female patients of child-bearing potential
should therefore be counselled on effective contraception
measures.
Calcium channel antagonists
In patients with confirmed PAH, the completion of a vaso-
dilator trial using short acting agents such as NO, epo-
prostenol or adenosine at the time of right heart
catheterization is an important diagnostic component that
provides a guide to therapy.
S30 D. Montani et al.A decrease in mPAP of at least 10 mmHg that results in
a mPAP of <40 mmHg, without associated decrease in
cardiac output, identifies PAH patients who may have sus-
tained haemodynamic improvement and prolonged survival
with calcium channel antagonist treatment.50 However, this
haemodynamic pattern may not be prognostically relevant
to the PVOD population. Montani et al demonstrated that
PVOD patients showing a positive response to short acting
vasodilators that are treated with calcium channel antag-
onists may develop severe pulmonary oedema.1,58
Epoprostenol
In PAH that is idiopathic or associated with connective tissue
disease (CTD), chronic epoprostenol therapy has been
shown to improve symptoms, exercise capacity, quality of
life, pulmonary haemodynamics and survival.59,60 Despite
concerns that treatment with prostanoids may be associated
with acute pulmonary oedema,1,4 several cases of successful
outcomes using this approach have been reported. We have
recently shown that, in carefully selected individuals, epo-
prostenol may have a therapeutic role.58 Twelve patients
with advanced PVOD treated with continuous intravenous
epoprostenol at the French National Referral Centre, Cla-
mart, were examined. Because of the possibility of severe
adverse reactions, relatively slow increments in dose titra-
tion were made and high-dose diuretics were used. After
3e4 months of therapy, significant improvements in NYHA
functional class and haemodynamic indices were observed
in the group as a whole. Treatment was generally well
tolerated, with mild pulmonary oedema developing in only
one patient. Lung transplantation, which was proposed for
all patients (median 2.4 months from initiation of epopros-
tenol), was successfully performed in 10 cases.58 These
results suggest that cautious use of intravenous epoproste-
nol might be helpful in the management of these patients as
a bridge to lung transplantation.58 However, durable
improvements in clinical and haemodynamic indices are
uncommon, and treatment with epoprostenol should be
considered as a bridge to lung transplantation only and not
an alternative to transplantation.
Other PAH-specific therapies
Several orally active agents that possess both vasodilatory
and antiproliferative effects are now licensed for use in
PAH of different aetiologies. However, there are only scant
data regarding use of such treatments in PVOD patients.
Rare instances of cases successfully managed using single
drug regimens of bosentan (a non-selective endothelin
antagonist)61 and sildenafil (a selective inhibitor of phos-
phodiesterase type-5) have been described.62,63 Despite
these encouraging reports, use of these therapies may
confer increased risk of acute pulmonary oedema in
a similar fashion to epoprostenol3 and should be restricted
to those with expertise in the management of patients with
PVOD in specialized centres. We have recently described
the first report of pulmonary oedema that developed
following initiation of sildenafil in a patient already
receiving bosentan therapy.64 This observation confirms
that use of combinations of PAH-specific agents in a “goal-
oriented” strategy should be undertaken with caution in
PVOD, even if first-line monotherapy is not complicated by
the occurrence of pulmonary oedema.64A number of cases of PVOD managed using different
inhaled therapies have been reported. Clinically important
beneficial effects using long term inhaled NO, either alone
or in combination with the prostacyclin analogue iloprost,
suggest a potential application in advanced disease.56,65 It
is important to note, however, that while several successful
outcomes using PAH-specific therapies have been published
in the medical literature, evidence for a consistent bene-
ficial effect in PVOD is lacking and more effective drug
treatments are needed.
Immunomodulatory agents
Successful outcomes using regimens that combine gluco-
corticoids with immunosuppressive drugs such as cyclo-
phosphamide have been reported for PAH complicating
sarcoidosis, SLE and MCTD patients. However, a significant
treatment effect on coexistent parenchymal lung disease
may, at least in part, have accounted for the clinical
improvements observed in these patients using this
strategy.66 Furthermore, initiation of immunosuppressive
therapy as first-line treatment in PAH associated with
scleroderma has no significant effect on functional class or
pulmonary haemodynamics.67 Although immunosuppressive
therapy may have a limited role in selected cases of PVOD
associated with connective tissue disease, there are
currently no data to support the wider use of steroids or
other immunomodulatory agents in PVOD in the absence of
coexistent inflammatory parenchymal lung disease.
Lung transplantation
Despite encouraging therapeutic discoveries, PVOD remains
an incurable disease and the prognosis for the majority of
patients is poor. Once the diagnosis of PVOD is established,
survival beyond two years is unusual, even with drug
treatment.5 When the disease occurs in the paediatric
population, disease progression is often even more rapidly
fatal.68,69 Currently, transplantation (lung or combined
heartelung) is considered the only therapeutic alternative
that offers durable clinical improvement and a potential
survival benefit.5 Early referral for transplant assessment is
therefore recommended. The possibility of disease recur-
rence in the transplanted lung has been reported in an
isolated case report in a heartelung transplant recipient,70
though no episodes of disease recurrence have been
described since this report. No disease recurrences have
been observed in PVOD patients from the French National
Pulmonary Hypertension Referral Centre that have been
undergone lung transplantation.
Future directions
There is now a wealth of accumulated clinical experience
with strategies employing combinations of PAH-specific
drugs in order to target the multifarious aberrant molec-
ular pathways characteristic of the disorder and thereby
theoretically enhance therapeutic gain. Indeed, this
approach is routinely pursued in many expert centres,
despite a lack of robust evidence demonstrating additional
clinical benefit.71 Theoretically, the risk of pulmonary
Pulmonary veno-occlusive disease S31oedema developing in the context of PVOD might be further
increased by using a regimen involving more than one
pulmonary vasodilator.64 However, in patients with severe
disease and poor expected survival time, cautious intro-
duction of additional treatments has been attempted in the
hope of slowing clinical deterioration. Nonetheless, expe-
rience is extremely limited to date and because of the risk
of severe pulmonary oedema, this approach is not recom-
mended outside of expert centres.
As our understanding of the pathobiology of PAH
increases, so does the identification of possible therapeutic
targets and potential novel treatments. Further studies are
needed in order to determine whether these therapies
might have any role in the PVOD population.
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